The OCGN stock forecast 2022 outlook suggests that Ocugen's stock may struggle in the short term. (See OCGN stock analysis on TipRanks). Sie knnen Ihre Einstellungen jederzeit ndern, indem Sie auf unseren Websites und Apps auf den Link Datenschutz-Dashboard klicken. The company has a gene therapy platform as well as two preclinical compounds that aim to treat retinal diseases. OCGN Ocugen Inc 155,223 $0.9721 $0.0263 (2.63%) Still, Ocugen investors who bought one year ago and held on have generated a huge return on their investment. Theres even room for more lines. Its top officers have experience at Pfizer (NYSE:PFE) and other well-respected pharmaceutical and biotechnology companies. Biotechnology stocks like Ocugen (NASDAQ:OCGN) are among the markets riskiest plays. The newly renamed Ocugen stock kept declining through year-end, but has managed to stage a bit of a rally in 2020, gaining 15% year-to-date. On its first trading day as OCGN stock, it lost almost 64% of its value and closed that day at $2.85 per share. Probably the most important thing to do after Ocugen's crash, though, is to identify lessons learned and apply them to future investing decisions. It is focused on discovering, developing and commercializing therapies which address rare and underserved eye diseases. Will Be Even Bigger Than Your Wildest Expectation, 7 Over-$100 Stocks That Are Worth Every Penny, Louis Navellier and the InvestorPlace Research Staff, 5 Penny Cryptos With the Most Potential for Growth. The content is intended to be used for informational purposes only. There's no way, however, to know what the COVID-19 vaccine market dynamics will be two years from now. If OCU300 is approved, theres a reasonably large market. As of this writing, Matt did not hold a position in any of theaforementioned securities. Just a few days ago, Ocugen (NASDAQ: OCGN) was flying high with shares up more than 460% year to date. Those lessons will vary between different investors, but I'll point out a major one to keep in mind. Shares of Ocugen (OCGN 4.03%) were crashing 19.2% lower as of 11:23 a.m. 7 Penny Stocks Poised for Explosive Growth in 2023, With No Revenue or Approved Treatments, Ocugen Stock Is a Clear Sell. Like other life sciences companies involved in Covid-19 vaccine. market." Part of the proceeds will be used to support its partnership with Bharat. Investors appear to expect that Bharat's big win for Covaxin in India could translate to success for Ocugen in the U.S. On Dec. 22, Ocugen and Bharat announced a binding letter of intent to jointly develop Covaxin for the U.S. market. Our 3 Top Picks. You canfollow Will on Twitterat @HealyWriting. Custom BMW. Still, this stock is cheap for reasons that my colleague Josh Enomoto spelled out well. The Motley Fool has no position in any of the stocks mentioned. The worst news was that another late-stage clinical study will likely be required to support the regulatory filing. By the beginning of March, the stock was still trading at 45 cents as news of the coronavirus spreading in China prompted concerns about a U.S. pandemic. 1125 N. Charles St, Baltimore, MD 21201. That's right -- they think these 10 stocks are even better buys. Emergency Use . How long might it take for Ocugen to win full FDA approval for Covaxin? 10 stocks we like better than Ocugen, Inc.When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Making the world smarter, happier, and richer. UPDATE 1-Soccer-Traore on target as Wolves stun wasteful Spurs, Peruvian communities to resume blockade of crucial "mining corridor", One student loan forgiveness effort 'hasnt gotten the attention it deserves': expert, RPT-Death toll in strike on Ukraine's Zaporizhzhia rises to 11 - officials, Soccer-Traore on target as Wolves stun wasteful Spurs. The median estimate. InvestorPlace - Stock Market News, Stock Advice & Trading Tips. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. It has no treatments to offer the market. 1125 N. Charles St, Baltimore, MD 21201. This decision. The short answer is: everything. Investors who have owned stocks in the last year have generally experienced some big gains. Do not expect this to become the biotech who made good like Biogen (NASDAQ:BIIB). The odds of Ocugen stock winding up at zero are material. Instead of buying a piece of the S&P 500 or Nasdaq or even better, a common sense mega-holding like Apple (NASDAQ:AAPL) or Amazon investors in OCGN stock took on a high-risk investment and for months saw negative returns. Ill be sticking to the stocks that are actually working. Companies will inevitably be optimistic about their prospects for success (at least publicly). But there is no question some big-name stocks performed better than others along the way. CanSinoBio will receive some of the profits, but Ocugen still would skyrocket with FDA approval and ensuing revenue and there are more products in the pipeline. 1 Reason to Buy Ocugen in 2023 and 2 Reasons to Sell, 3 Under-the-Radar Stocks With 590% to 772% Upside in 2023, According to Wall Street, 2 Reasons to Avoid a Roth 401(k) for Your Retirement Savings, Warren Buffett's Latest $2.9 Billion Buy Brings His Total Investment in This Stock to $66 Billion in 4 Years, Want $1 Million in Retirement? OCU300 already has received an orphan drug designation from the U.S. Food & Drug Administration for oGVHD; there is no currently approved treatment in the U.S. Copyright 2023 InvestorPlace Media, LLC. A $30 million market capitalization doesnt mean Ocugen has no chance. CEO Shankar Musunuri stated that he was "pleased to say" that Ocugen was in discussions with the FDA about the data it had submitted for the pediatric EUA. Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. The Motley Fool has a disclosure policy. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide. Moreover, Histogenics existed to treat orthopedic conditions, while Ocugen focused on rare eye diseases. Nasdaq After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. Still, Ocugen investors who bought one year ago and held on have generated a huge return on their. To find good ideas for coronavirus stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights. What should investors do now? Some investors had set their hopes on the FDA being more lenient with pediatric use of Covaxin. The FDA's decision not to issue EUA really wasn't all that surprising, though. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. Now, with the stock trading near the 40-cent per share level, its prospects have taken a dramatic turn for the worse. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. An unprofitable biotech that focused on commercializing therapies to cure blindness prior to the present pandemic, Ocugen ( OCGN) stock took on a new life on December 22, when it announced. Will Be Even Bigger Than Your Wildest Expectation, 7 Over-$100 Stocks That Are Worth Every Penny, Louis Navellier and the InvestorPlace Research Staff, 5 Penny Cryptos With the Most Potential for Growth. A bout of buying in late July sent shares from 20 cents apiece to above 90 cents a share a few days. Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. These symbols will be available throughout the site during your session. Maybe. Other than an emphasis on cell therapies, the companies had almost nothing in common. Ocugen sold $25 million of stock in a private placement before the merger. Ocugen Inc Stock - OCGN Share Price Today, News and Discussion 0.90% SPY 0.59% QQQ 0.60% TSLA 6.12% SI 60.35% CRM 11.51% RIVN 0.32% ARKK 0.96% RLY.X 56.44% PLUG 6.72% V 0.22% CDIO 13.87% RETA 5.92% More Advertisement 3rd Party Ad. You never know when they will suddenly go on a squeeze. Unfortunately, both the merger and the reverse split have failed to stem the decline of former Histogenics stock. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off. All rights reserved. Ocugen had to go an unusual route to go public. Do not expect a recovery in Ocugen stock. Those reverse splits generally are poorly received by the market, even if in theory they should have little to no practical impact on trading. Hence, instead of ruining just two lives, this new Ocugen may be destroying the investment future of all who buy. After all, one cannot expect Ocugen stock to cure its ills when the company itself has fallen into critical condition. Keith Speights owns shares of Pfizer. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. For most of its history, what we now know as Ocugen stock was Histogenics, a cell therapy company focused on orthopedics. It means that raising capital will be more difficult going forward. COVID-19 vaccines from Pfizer and Moderna are already on the market in the U.S. with efficacy levels of 94% or greater. 86% of retail CFD accounts lose money, Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023, Ocugen upgraded at Chardan citing attractive entry point ahead of catalysts, Analysts Are Bullish on These Healthcare Stocks: Theratechnologies (THTX), Ocugen (OCGN), Ocugen (OCGN) Gets a Buy from H.C. Wainwright, Mizuho Securities Sticks to Their Buy Rating for Ocugen (OCGN), Ocugen (OCGN) Q4 2022 Earnings Call Transcript, Why Catalyst Biosciences Shares Are Trading Higher By 105%; Here Are 20 Stocks Moving Premarket, Registration on or use of this site constitutes acceptance of our. In fact, $1,000 in Ocugen stock bought on Aug. 9, 2020, would be worth about $15,100 today. Copyright Since its merger, Ocugen stock has continued the decline that occurred under the company that it took over, Histogenics. This is most likely a result of the stocks meteoric rise and analysts inability to turnaround new price targets so quickly. 5 Hypergrowth Stocks With 10X Potential in 2023, Robert Bollinger: Meet the Man Behind Mullens Push Into Commercial EVs, A.I. The all-time high Ocugen stock closing price was, The average Ocugen stock price for the last 52 weeks is. Ocugen ( NASDAQ: OCGN) has been one of the more polarizing story stocks of 2021. Conditions only seem to get worse for Ocugen (NASDAQ:OCGN). Related Link: If You Invested $1,000 In Moderna Stock One Year Ago, Here's How Much You'd Have Now. The huge gain came after the company's partner, Bharat Biotech, received emergency use authorization. Most biotech companies have intriguing stories on paper; Ocugen is no different. In fact, the SPDR S&P 500 (NYSE:SPY) total return over the last 12 months is 34.2%. Stock Price Forecast The 6 analysts offering 12-month price forecasts for Ocugen Inc have a median target of 4.75, with a high estimate of 8.00 and a low estimate of 3.00. Accordingly, the analyst rates OCGN a Neutral (i.e. The agreement stipulates Ocugen will hold the vaccines U.S. rights, and the remaining details are expected to be finalized over the coming weeks. Ocugen. Emergency Use Authorization (EUA) for Covaxin, the COVID-19 vaccine developed by Ocugen's partner, Bharat Biotech. Why Ocugen Stock Is Crashing Today By Keith Speights - Mar 4, 2022 at 11:42AM Key Points The FDA gave a thumbs-down to Ocugen's EUA request for the pediatric use of Covaxin. However, an EUA in India doesn't mean that Covaxin is a slam dunk to win EUA in the U.S., as well. In December, Ocugen stated that it had put together an advisory board of "leading academic and industry experts to evaluate the clinical and regulatory path to approval in the U.S. The broad point here is that, even with a ~$30 million market capitalization (based on updated share count information disclosed in an 8-K filing on Dec. 9), this is a company with a legitimate opportunity. MALVERN, Pa., May 29, 2018 /PRNewswire/ -- Ocugen, Inc., a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved ocular diseases, today announced that it will present at the 2018 BIO International Convention, taking place June 4-7, 2018, in Boston. Ocugen Inc. stock rises Wednesday, outperforms market Feb. 22, 2023 at 5:14 p.m. CanSinoBio is a legitimate player in the industry; the companys market cap is near $2 billion after a nice rally in recent weeks. The stock ultimately hit its 2020 low on June 1 at a price of just 17 cents. Like Pfizer's BNT162b2 and Moderna's mRNA-1273, it requires two doses. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. Shares of Ocugen ( OCGN -3.10%) fell on Tuesday after an analyst sounded a note of caution to investors. And its at least possible that OCGN could wind up being a winner. Article printed from InvestorPlace Media, https://investorplace.com/2019/12/no-pathway-forward-for-ocugen-stock/. The risk-reward proposition for Ocugen is obviously much different now than it was when individuals were buying the stock over the last several months. Ocugen, previously a private company, instituted a reverse merger, which they completed on Sep. 30. But theres a big difference in having an edge flipping sub-$5 stocks vs. combing over this group as an investor looking for sound fundamentals and a mistakenly low stock price. Ocugen isnt a promotional, fly-by-night penny stock. Over the next few weeks, Ocugen is expected to meet with the FDA to discuss how to advance COVAXINs development. If Ocugen goes up, you can still profit. On June 10, though, Ocugen announced that the U.S. Food and Drug Administration (FDA) had effectively shut the door on an EUA filing. Wenn Sie Ihre Auswahl anpassen mchten, klicken Sie auf Datenschutzeinstellungen verwalten. Some of the names will rally big, putting together epic squeezes that can double or triple the stock prices in just a few days. Add in a $31 million market capitalization and potentially significant cash burn, and Ocugen stock self-evidently is not for risk-averse investors. Nor should one look forward to OCGN stock to becoming the next GW Pharmaceuticals (NASDAQ:GWPH) or Cara Therapeutics (NASDAQ:CARA). quotes delayed at least 15 minutes, all others at least 20 minutes. Keith Speights for Objective investors could have clearly seen then that there actually were significant reasons to be concerned. Indeed, the price broke below the 24 December 2018 low at 4.81 and is currently attempting a return move. If you already owned Ocugen stock before the company's disappointing news, you have several alternatives. The first is that Ocugen is facing potential delisting from the NASDAQ given that its share price still sits well below $1. But realizing value in practice usually is a difficult endeavor. So, what goes wrong? While it feels cool to buy a thousand shares of OCGN stock vs. a few shares of Amazon (NASDAQ:AMZN), save yourself the heartache. It is very important to do your own analysis before making any investment. Names like Ocugen (NASDAQ:OCGN) arent trading for about 50 cents apiece by accident. The company stated that it will pursue a path to file for full FDA approval of Covaxin. For investors new to the story, there are some positives when it comes to OCGN stock. The FDA typically takes 60 days to accept a regulatory filing then 10 months to make an approval decision. The S&P 500 has rallied 52.9% from the March low to its highs on August 6. It's hard to say for sure. See disclosure here. That's not going to happen now. (To watch Ramakanths track record, click here), In contrast, all 3 other analysts who have recently posted an Ocugen review rate the stock a Buy. Conditions have only become worse since that time. Under the terms of the agreement, Ocugen is entitled to 45% of the profits from the commercialization of Covaxin in the U.S. and Canada. Ramakanth believes the broad immunity targeting different components of the virus could potentially provide better protection against emerging mutant viruses, such as the one currently circulating in the UK. With this in mind, in the Phase 1 study, COVAXIN has shown robust antibody responses against spike (S1) protein, receptor-binding domain (RBD) and the nucleocapsid (N) protein of SARS-CoV-2. If were playing that game then Im buying LEAP call options on Apple and Amazon in March. The market capitalization of Relmada Therapeutics (NASDAQ:RLMD) went from under $10 million at the end of 2017 to over $500 million at the moment. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. If it goes down, your loss won't be as great as it would be if you held onto all of your shares. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. Axsome Therapeutics (NASDAQ:AXSM) had an equity value below $75 million in March 2017; its now worth over $3 billion after rising over 1,000% last year. Typically, I care little about financials with biotechs. Histogenics itself highlights the risks involved in small-cap biotech. All rights reserved. The reverse merger that brought Ocugen to the public markets led to huge losses but some investors are buying the dip. Learn More. When the market crashed during the U.S. pandemic outbreak in March, shares of vaccine makers understandably soared as work began on developing vaccines to fight COVID-19. Importantly, neither Bharat nor Indian regulators revealed the efficacy of the vaccine. The company initiated its Phase 3 trial of OCU300 back in July 2018. OCGN | Ocugen Inc. Stock Price & News - WSJ Ocugen Inc. OCGN (U.S.: Nasdaq) REAL TIME 12:30 PM EST 02/21/23 $0.9819USD -0.0981 -9.08% Volume 3,761,699 65 Day Avg Vol 5,026,332 1 Day Range. The second is that the balance sheet still needs some help. However, even from this limited vantage point, OCGN appears destined to fail. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. Generally, financial analysts struggle with this sector because these equities rise and fall not on revenue or earnings, but the success of clinical trials. Please check your download folder. That's right -- they think these 10 stocks are even better buys. For priority reviews, the timeline for an approval decision is reduced to six months. The Motley Fool has a disclosure policy. Theres even room for more lines. It took Moderna roughly 10 months from the initiation of the late-stage study for its COVID-19 vaccine to the point where the company filed for full FDA approval. It brings in no revenue. 7 Travel Stocks to Buy Banking On Pent-Up Demand. Lorem ipsum dolor sit amet, consectetur adipiscing elit. You can be a growth investor, futures trader, deep-value investor, a day trader, options player, or a dividend aficionado. Type a symbol or company name. All rights reserved. Ocugen executives even sounded cautiously optimistic in the company's fourth-quarter conference call last month. It's easy to become such a huge fan of a stock that you lose objectivity about its prospects. Type a symbol or company name. Our 3 Top Picks. Bharat's offering COVAXIN, a whole-viron inactivated COVID-19 vaccine candidate, has already shown promise in Phase 1 and 2 clinical trials in India and the enrollment of 26,000 subjects for the Phase 3 study is currently underway. That doesnt mean success is guaranteed. The sale of NeoCart, which still is pending, can bring in another $8 million, based on the current agreement. Investors were hopeful that the small drugmaker would be able to win U.S. The FDA gave a thumbs-down to Ocugen's EUA request for the pediatric use of Covaxin. And while Ocugen will need more capital at some point, the company at least has time to push OCU300 forward and get its story out to investors. Shares fell 72% on the news, and kept falling after Histogenics decided to suspend development of the product in December 2018. However, sometimes the optimism isn't justified. Matthew McCall left Wall Street toactually helpinvestors by getting them into the worlds biggest, most revolutionary trends BEFORE anyone else. If you use our chart images on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. The reverse merger with Histogenics was a disappointment, but the purchase price for the NeoCart intellectual property suggests that company had little chance of survival on its own. The next key catalyst for the biotech stock could be the announcement of the details of the plan to win EUA for Covaxin in the U.S. market. Keith Speights has no position in any of the stocks mentioned. Some were undoubtedly anticipating a relatively quick EUA win for Covaxin followed by strong U.S. sales for the COVID-19 vaccine. Weve now already seen a 50% correction in the stock price, with shares changing hands around 46 cents per share. David and Tom just revealed what they believe are the ten best stocks for investors to buy right now and Ocugen, Inc. wasn't one of them! The generic form of brimonidine, the active ingredient, is not approved for the condition, according to Ocugens most recent presentation. The company is led by CEO and Co-founder, Shankar Musunuri, and entered into the public equity market in 2019 via. With No Revenue or Approved Treatments, Ocugen Stock Is a Clear Sell Amryt Pharma releases Q-2 how to setup copy trading labrador gold stock that show strong revenue growth as The first split for NKE took place on October 08, Below, we'll pit these two dominant consumer-discretionary giants against each other, with an eye toward long-term . Its certainly possible the deal will fall through, leaving Ocugen with just the $15.8 million in cash with which it closed the third quarter, according to its 10-Q. The stock dropped as low as 26 cents during the height of the pandemic fears in March 2020. *Stock Advisor returns as of June 7, 2021. Click here to see what Matt has up his sleeve now. Unfortunately for longs, OCGN is much closer to the worst of conditions. We have provided a few examples below that you can copy and paste to your site: Your data export is now complete. ET on Friday. Do Not Sell My Personal Information (CA Residents Only). As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. Healthy companies do not undergo 1-for-60 reverse stock splits like this one did in September 2019. The average price target among the five analysts covering the stock is $6, suggesting 27.9% downside from current levels. Ocugen shares jumped to $3.50 on massive volume in December when the Covaxin partnership was announced. 7 Penny Stocks Poised for Explosive Growth in 2023, Ocugen Stock Is Not for the Faint of Heart. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. CanSinoBio will be able to fund much of the development of OCU300, Ocugens flagship product that targets oGVHD (ocular graft versus host disease), a common complication of bone marrow transplants. Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Bei der Nutzung unserer Websites und Apps verwenden wir, unsere Websites und Apps fr Sie bereitzustellen, Nutzer zu authentifizieren, Sicherheitsmanahmen anzuwenden und Spam und Missbrauch zu verhindern, und, Ihre Nutzung unserer Websites und Apps zu messen, personalisierte Werbung und Inhalte auf der Grundlage von Interessenprofilen anzuzeigen, die Effektivitt von personalisierten Anzeigen und Inhalten zu messen, sowie, unsere Produkte und Dienstleistungen zu entwickeln und zu verbessern. Guys, theres no revenue here! From a broader perspective, the risk is the same as it is across biotech: most candidates fail. Source: Chart courtesy of StockCharts.com. The $25 million private placement executed before the merger brought in much-needed cash. Another alternative is to sell some or all of your Ocugen stock and invest the money elsewhere. I will just say this on Ocugen: Theres a reason it trades for sub-$1 after hitting resistance near $180 in 2018. Malvern-based biopharmaceutical company Ocugen completed its previously announced $100 million private stock sale. The post There Are So Many Stocks to Buy Ocugen Isnt One of Them appeared first on InvestorPlace. It announced on Dec. 9 of last year 17 months later that it was 50% through enrollment. Ocugen Inc. is a clinical stage biopharmaceutical company. However, the marriage of Histogenics and Ocugen looks destined to end in a suicide pact instead of a mere divorce. Without NeoCart, that burn likely comes down. From a near-term standpoint, there are two key risks. Honestly, OCGN stock is unlikely to survive. The latest closing stock price for Ocugen as of March 03, 2023 is. After encouraging preliminary results, Ocugen began trying to sell 100 million doses of the vaccine in February. OCGN does not even appear to have an apparent reason to exist. Thats not a new problem: a previous Phase 1/2 study, according to the prospectus, was discontinued early due to slow enrollment. The company noted that additional trials may be required as well. The company has no revenue, runs an annual deficit, and does not generate positive free cash flow. Sign up below to get this incredible offer! In the late summer of 2018, the stock crashed below $1 per share as investors sold off following a failed phase three trial. The Motley Fool->. Even before that point, the most promising candidates generally can find funding. Concerns about the delta variant, the potential need for annual booster shots and the possibility of expanding the vaccines to children have investors hopeful that Covaxin will still eventually be a huge payoff for Ocugen. 5 Hypergrowth Stocks With 10X Potential in 2023, Robert Bollinger: Meet the Man Behind Mullens Push Into Commercial EVs, A.I. There's still a chance that the vaccine could receive a green light in Canada. Pricing likely would be favorable, given the lack of alternative treatments. Please check your download folder. The Ocugen deal is a way to salvage some limited value. One thing seems certain, however:Ocugens fate as an investment is closely tied to the ultimate outcome of Covaxin. *Average returns of all recommendations since inception. Copyright 1125 N. Charles St, Baltimore, MD 21201. Ocugen Chairman and CEO Shankar Musunuri Ocugen The company's stock opened at $8.24 per share Tuesday, up 96 cents. Ocugen has responded to Health Canada regarding deficiencies identified with its regulatory filing for Covaxin. Keith Speights for Thats one of the best rallies weve seen in that amount of time (95 trading sessions, 136 days). Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Until July 20, when OCGN stock jumped about 20%, shares were down 21% from the March low. Histogenics shareholders then received about 14% of the company, according to the merger prospectus.
Moderately Sorted Sediment,
Pottery Barn In Transit From Distribution Center,
Hwy 2 Accident Sultan, Wa,
National Underclassmen Combine,
Private Transportation From Nassau Airport To Atlantis,
Articles O
